Chimeric PCV2 vaccine eliminating live-virus disease risk in
This technology provides a method for creating a safe, effective vaccine against Porcine Circovirus Type 2 (PCV2), a virus that causes wasting disease in young pigs. Researchers created a 'chimeric' virus by taking a harmless version of the virus (PCV1) and swapping in specific genetic instructions from the dangerous version (PCV2) that trigger an immune response. The resulting hybrid virus acts as a live vaccine that looks like the disease to a pig's immune system but lacks the ability to actually make the animal sick. The patent also covers specific genetic mutations that further improve the stability and effectiveness of this vaccine approach.
What you could build
A live-attenuated chimeric vaccine for the swine industry to prevent Postweaning Multisystemic Wasting Syndrome (PMWS).
Who in Virginia should care
Virginia's substantial pork production industry and veterinary research centers (like the VA-MD College of Veterinary Medicine) are primary stakeholders in swine health innovations.
Readiness: Prototype likely
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
- Granted
- November 15, 2011
- Status
- Granted patent
- Patent number
- 8058048
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.